黄园园, 高尔建, 袁经权, 吴燕春, 饶小平, 王微. 苦楝皮中一个新的柠檬苦素类化合物及其抗肝癌活性J. 药学学报, 2026, 61(2): 547-552. DOI: 10.16438/j.0513-4870.2025-1252
引用本文: 黄园园, 高尔建, 袁经权, 吴燕春, 饶小平, 王微. 苦楝皮中一个新的柠檬苦素类化合物及其抗肝癌活性J. 药学学报, 2026, 61(2): 547-552. DOI: 10.16438/j.0513-4870.2025-1252
HUANG Yuan-yuan, GAO Er-jian, YUAN Jing-quan, WU Yan-chun, RAO Xiao-ping, WANG Wei. A new limonoid compound from the bark of Melia azedarach and its anti-hepatocarcinoma activityJ. Acta Pharmaceutica Sinica, 2026, 61(2): 547-552. DOI: 10.16438/j.0513-4870.2025-1252
Citation: HUANG Yuan-yuan, GAO Er-jian, YUAN Jing-quan, WU Yan-chun, RAO Xiao-ping, WANG Wei. A new limonoid compound from the bark of Melia azedarach and its anti-hepatocarcinoma activityJ. Acta Pharmaceutica Sinica, 2026, 61(2): 547-552. DOI: 10.16438/j.0513-4870.2025-1252

苦楝皮中一个新的柠檬苦素类化合物及其抗肝癌活性

A new limonoid compound from the bark of Melia azedarach and its anti-hepatocarcinoma activity

  • 摘要: 采用硅胶、SephadexLH-20、MCI、制备型高效液相等色谱技术对苦楝(Melia azedarach L.) 树皮95%、85%乙醇提取物进行分离纯化, 从中分离得到了3个柠檬苦素类化合物, 根据其理化性质及其波谱数据分别鉴定为29-O-ethyl neoazedarachin D (1)、29-O-meliarachin G (2)、toosendanin (3), 其中化合物1为新化合物, 化合物2为新的天然产物, 首次从植物中分离得到。采用MTT法评价化合物1~3体外抗肝癌活性, 结果表明化合物1~3对HepG-2、Hep3B细胞都具有不同程度的抑制作用, 其中化合物3对HepG-2细胞的抑制作用与阳性药顺铂相当。此外, 化合物1~3抗HepG-2细胞的IC50值分别为38.67 ± 1.336、28.21 ± 1.028、8.21 ± 1.231 μg·mL-1, 抗Hep3B细胞的IC50值分别为47.36 ± 1.008、35.69 ± 1.217、15.10 ± 1.017 μg·mL-1

     

    Abstract: Three limonoids were isolated and purified from the 95%, 85% ethanol extracts of Melia azedarach using silica gel column chromatography, Sephadex LH-20 column chromatography, MCI column chromatography, and preparative RP-HPLC. Their structures were determined based on physicochemical properties and spectral data, and they were identified as 29-O-ethyl neoazedarachin D (1), 29-O-meliarachin G (2), toosendanin (3). Compound 1 is a new limonoid, while compound 2 is a new natural product isolated from plants for the first time. The in vitro anti-hepatocarcinoma activities of compounds 1-3 were evaluated by MTT assay. The results showed that compounds 1-3 exhibited different degrees of inhibitory effects on both HepG-2 and Hep3B cell lines, and the inhibitory effect of compound 3 on HepG-2 cells was comparable to that of the positive drug cisplatin. In addition, compounds 1-3 exhibited IC50 values of 38.67 ± 1.336, 28.21 ± 1.028 and 8.21 ± 1.231 μg·mL-1 against HepG-2 cells, and 47.36 ± 1.008, 35.69 ± 1.217 and 15.10 ± 1.017 μg·mL-1 against Hep3B cells, respectively.

     

/

返回文章
返回